Cargando…
Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V. and International Society of Chemotherapy.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293467/ https://www.ncbi.nlm.nih.gov/pubmed/32544570 http://dx.doi.org/10.1016/j.ijantimicag.2020.106052 |
| _version_ | 1783546311237173248 |
|---|---|
| author | Hong, Sun In Ryu, Byung-Han Chong, Yong Pil Lee, Seungjun Kim, Sunjoo Kim, Ho Cheol Hong, Kyung-Wook Bae, In-Gyu Cho, Oh-Hyun |
| author_facet | Hong, Sun In Ryu, Byung-Han Chong, Yong Pil Lee, Seungjun Kim, Sunjoo Kim, Ho Cheol Hong, Kyung-Wook Bae, In-Gyu Cho, Oh-Hyun |
| author_sort | Hong, Sun In |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7293467 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier B.V. and International Society of Chemotherapy. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72934672020-06-14 Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b Hong, Sun In Ryu, Byung-Han Chong, Yong Pil Lee, Seungjun Kim, Sunjoo Kim, Ho Cheol Hong, Kyung-Wook Bae, In-Gyu Cho, Oh-Hyun Int J Antimicrob Agents Letter to the Editor Elsevier B.V. and International Society of Chemotherapy. 2020-08 2020-06-13 /pmc/articles/PMC7293467/ /pubmed/32544570 http://dx.doi.org/10.1016/j.ijantimicag.2020.106052 Text en © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Hong, Sun In Ryu, Byung-Han Chong, Yong Pil Lee, Seungjun Kim, Sunjoo Kim, Ho Cheol Hong, Kyung-Wook Bae, In-Gyu Cho, Oh-Hyun Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b |
| title | Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b |
| title_full | Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b |
| title_fullStr | Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b |
| title_full_unstemmed | Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b |
| title_short | Five severe COVID-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b |
| title_sort | five severe covid-19 pneumonia patients treated with triple combination therapy with lopinavir/ritonavir, hydroxychloroquine, and interferon β-1b |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293467/ https://www.ncbi.nlm.nih.gov/pubmed/32544570 http://dx.doi.org/10.1016/j.ijantimicag.2020.106052 |
| work_keys_str_mv | AT hongsunin fiveseverecovid19pneumoniapatientstreatedwithtriplecombinationtherapywithlopinavirritonavirhydroxychloroquineandinterferonb1b AT ryubyunghan fiveseverecovid19pneumoniapatientstreatedwithtriplecombinationtherapywithlopinavirritonavirhydroxychloroquineandinterferonb1b AT chongyongpil fiveseverecovid19pneumoniapatientstreatedwithtriplecombinationtherapywithlopinavirritonavirhydroxychloroquineandinterferonb1b AT leeseungjun fiveseverecovid19pneumoniapatientstreatedwithtriplecombinationtherapywithlopinavirritonavirhydroxychloroquineandinterferonb1b AT kimsunjoo fiveseverecovid19pneumoniapatientstreatedwithtriplecombinationtherapywithlopinavirritonavirhydroxychloroquineandinterferonb1b AT kimhocheol fiveseverecovid19pneumoniapatientstreatedwithtriplecombinationtherapywithlopinavirritonavirhydroxychloroquineandinterferonb1b AT hongkyungwook fiveseverecovid19pneumoniapatientstreatedwithtriplecombinationtherapywithlopinavirritonavirhydroxychloroquineandinterferonb1b AT baeingyu fiveseverecovid19pneumoniapatientstreatedwithtriplecombinationtherapywithlopinavirritonavirhydroxychloroquineandinterferonb1b AT choohhyun fiveseverecovid19pneumoniapatientstreatedwithtriplecombinationtherapywithlopinavirritonavirhydroxychloroquineandinterferonb1b |